Related Experiment Video
Updated: Mar 23, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Rosuvastatin Reduces Blood Viscosity in Patients with Acute Coronary Syndrome
Lae-Young Jung1, Sang-Rok Lee1, Jin-Mu Jung2
1Division of Cardiology, Chonbuk National University Hospital and Chonbuk National University Medical School, Jeonju, Korea.
Insights
Statins significantly reduce whole blood viscosity (WBV) in acute coronary syndrome (ACS) patients. One month of rosuvastatin treatment lowered WBV in statin-naïve individuals, indicating statins
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Biophysics
Background:
- Wall shear stress is implicated in atherosclerosis progression and plaque rupture.
- Limited research exists on statins' impact on whole blood viscosity (WBV) in acute coronary syndrome (ACS) patients.
- This study investigates the effect of statin therapy on WBV in ACS patients.
Purpose of the Study:
- To determine the effect of statin therapy on whole blood viscosity (WBV) in patients with acute coronary syndrome (ACS).
- To compare WBV between patients with prior statin use and statin-naïve patients.
- To assess the change in WBV after one month of rosuvastatin treatment in statin-naïve ACS patients.
Main Methods:
- Prospective enrollment of 189 ACS patients (52 STEMI, 84 NSTEMI, 53 UA).
- Patients divided into two groups: prior statin users (n=51) and statin-naïve (n=138).
- Measurement of systolic (SBV) and diastolic blood viscosity (DBV) at baseline and one month post-treatment with rosuvastatin (16.2±4.9 mg/day).
Main Results:
- Baseline WBV (SBV and DBV) was significantly higher in statin-naïve patients compared to prior statin users (p<0.003).
- One month of rosuvastatin treatment significantly decreased WBV (SBV and DBV) in statin-naïve patients (p<0.044).
- Low-density lipoprotein cholesterol levels showed no association with WBV at baseline or follow-up.
Conclusions:
- Prior statin medication is a significant factor in reducing WBV in ACS patients.
- Short-term rosuvastatin treatment effectively decreases WBV in statin-naïve ACS patients.
- Statin therapy demonstrates a beneficial effect on hemorheological properties in ACS.
Background And Objectives:
Wall shear stress contributes to atherosclerosis progression and plaque rupture. There are limited studies for statin as a major contributing factor on whole blood viscosity (WBV) in patients with acute coronary syndrome (ACS). This study investigates the effect of statin on WBV in ACS patients.
Subjects And Methods:
We prospectively enrolled 189 consecutive patients (mean age, 61.3±10.9 years; 132 males; ST-segment elevation myocardial infarction, n=52; non-ST-segment elevation myocardial infarction, n=84; unstable angina n=53). Patients were divided into two groups (group I: previous use of statins for at least 3 months, n=51; group II: statin-naïve patients, n=138). Blood viscosities at shear rates of 1 s-1 (diastolic blood viscosity; DBV) and 300 s-1 (systolic blood viscosity; SBV) were measured at baseline and one month after statin treatment. Rosuvastatin was administered to patients after enrollment (mean daily dose, 16.2±4.9 mg).
Results:
Baseline WBV was significantly higher in group II ([SBV: group I vs group II, 40.8±5.9 mP vs. 44.2±7.4 mP, p=0.003], [DBV: 262.2±67.8 mP vs. 296.9±76.0 mP, p=0.002]). WBV in group II was significantly lower one month after statin treatment ([SBV: 42.0±4.7 mP, p=0.012, DBV: 281.4±52.6 mP, p=0.044]). However, low-density lipoprotein cholesterol level was not associated with WBV in both baseline (SBV: R2=0.074, p=0.326; DBV: R2=0.073, p=0.337) and after one month follow up (SBV: R2=0.104, p=0.265; DBV: R2=0.112, p=0.232).
Conclusion:
Previous statin medication is an important determinant in lowering WBV in patients with ACS. However, one month of rosuvastatin decreased WBV in statin-naïve ACS patients.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease IV: Preventive Measures
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...